ZBIO - CIK 0001953926
The table below shows Zenas BioPharma, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 |
|---|---|---|---|
| Operating cash flow | -$75.20M | -$37.05M | -$19.10M |
| Capital expenditure | $2.00K | $18.00K | $22.00K |
| Investing cash flow | $31.61M | -$86.27M | -$22.00K |
| Dividends paid | - | - | - |
| Stock buybacks | - | - | - |
| Financing cash flow | $433.48M | $99.00K | -$614.00K |
Zenas BioPharma, Inc. reported operating cash flow of -$172.33M for fiscal year 2025. That is down 44.0% from -$119.67M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.